<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381172</url>
  </required_header>
  <id_info>
    <org_study_id>CP OPT2009-009</org_study_id>
    <secondary_id>G030099</secondary_id>
    <nct_id>NCT01381172</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C</brief_title>
  <acronym>FIX-HF-5C</acronym>
  <official_title>Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%: FIX-HF-5C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impulse Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impulse Dynamics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this investigation is to evaluate the safety and effectiveness of the
      OPTIMIZER® System in subjects with medically refractory moderate-to-severe heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Impulse Dynamics FIX-HF-5C Study is a prospective, multicenter, randomized study to
      evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered
      by the implantable OPTIMIZER System in patients with NYHA class III and IV heart failure and
      an ejection fraction 25-45%. The study will involve the recruitment of 160 subjects at a
      total of up to 60 sites.

      Those subjects who fulfill all inclusion and exclusion criteria based upon baseline test
      results will be randomly assigned in a 1:1 ratio to either the OPTIMIZER System plus optimal
      medical therapy (OMT) or to a control group receiving OMT alone. All randomized subjects will
      be followed for 24 weeks and shall receive the same study related assessments throughout the
      course of the study. In addition, all subjects will continue to receive OMT for the treatment
      of their heart failure. Mortality will be reported out to 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in exercise tolerance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Exercise tolerance quantified by peak VO2 measured with cardiopulmonary exercise stress testing (CPX)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MLWHFQ</measure>
    <time_frame>24 weeks</time_frame>
    <description>Quality of life, as assessed by the Minnesota Living with Heart Failure (MLWHF) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak VO2 with respiratory exchange ratio (RER)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Peak VO2 with change in respiratory exchange ratio (RER) included as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA</measure>
    <time_frame>24 weeks</time_frame>
    <description>Heart failure class, as assessed by the New York Heart Association (NYHA) classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak VO2 with a peak RER of ≥1.05</measure>
    <time_frame>24 weeks</time_frame>
    <description>Peak VO2 in an analysis that only includes tests with a peak RER of ≥1.05.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>6 Minute Hall Walk</measure>
    <time_frame>24 weeks</time_frame>
    <description>Distance walked in 6 minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>VE/VCO2</measure>
    <time_frame>24 weeks</time_frame>
    <description>VE/VCO2 as measured during cardiopulmonary stress testing.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>NYHA Class III Heart Failure</condition>
  <condition>NYHA Class IV Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimizer System</intervention_name>
    <description>The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>CCM therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention: Optimal medical therapy</intervention_name>
    <description>The control group receives optimal medical therapy only.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are 18 years of age or older

          2. Subjects who are either male or female. Females of childbearing potential must be
             using a medically approved method of birth control and must agree to continue to use
             birth control throughout the study, or must be surgically sterilized (tubal ligation,
             hysterectomy) or post-menopausal for at least 1 year.

          3. Condition

               1. Subjects who have a baseline ejection fraction greater than or equal to 25% and
                  less than or equal to 45% by echocardiography determined by the echocardiography
                  core laboratory.

               2. Subjects who have been treated for heart failure for at least 90 days (including
                  treatment with a β-blocker for at least 90 days unless the subject is intolerant)
                  and are in New York Heart Association functional Class III and IV at the time of
                  enrollment.

               3. Subjects receiving appropriate, stable medical therapy during the 30 days prior
                  to enrollment for treatment of heart failure according to the region- specific
                  guideline recommendations. For patients with EF≤35%, this regimen shall consist
                  of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor
                  blocker and β-blocker. Stable is defined as no more than a 100% increase or 50%
                  decrease in dose.

               4. Subjects who, in the opinion of the Principal Investigator (based on the current
                  guidelines for clinical practice ), have a clinical indication for an implanted
                  cardiac defibrillator (ICD, e.g., EF≤35%) and/or pacemaker, must have an existing
                  device or agree to undergo implantation of such a device unless the patient
                  refuses to undergo the implantation of such device for personal reasons.

               5. Subjects who are willing and able to return for all follow-up visits.

        Exclusion Criteria:

          1. Subjects whose baseline peak VO2 is &lt;9 or &gt;20 ml O2/min/kg.

          2. Subjects who have a potentially correctible cause of heart failure, such as valvular
             heart disease or congenital heart disease.

          3. Subjects who have clinically significant angina pectoris, consisting of angina during
             daily life (i.e., Canadian Cardiovascular Society Angina score of II or more), an
             episode of unstable angina within 30 days of enrollment, or angina and/or ECG changes
             during exercise testing performed during baseline evaluation.

          4. Subjects who have been hospitalized for heart failure which required the use of
             inotropic support within 30 days of enrollment.

          5. Subjects who have a clinically significant amount of ambient ectopy, defined as more
             than 8,900 PVCs per 24 hours on baseline Holter monitoring.

          6. Subjects having a PR interval greater than 375 ms.

          7. Subjects who have chronic (permanent or persistent) atrial fibrillation or atrial
             flutter or those cardioverted within 30 days of enrollment.

          8. Subjects whose exercise tolerance is limited by a condition other than heart failure
             (e.g., angina, COPD, peripheral vascular disease, orthopedic or rheumatologic
             conditions) or who are unable to perform baseline stress testing.

          9. Subjects who are scheduled for a CABG or a PTCA procedure, or who have undergone a
             CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.

         10. Subjects who have a biventricular pacing system, an accepted indication for such a
             device, or a QRS width of 130ms or greater.

         11. Subjects who have had a myocardial infarction within 90 days of enrollment.

         12. Subjects who have mechanical tricuspid valve.

         13. Subjects who have a prior heart transplant.

         14. Subjects on dialysis.

         15. Subjects who are participating in another experimental protocol.

         16. Subjects who are unable to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Burkhoff, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Impulse Dynamics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Consultants</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of Mesa</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chan Heart Rhythm Institute</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Heart &amp; Rhythm Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pima Heart</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Sarver Heart Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale - New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital - Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Medical Group - Midwest Heart Foundation</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center - Cardiovascular Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryan Heart LGH</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>69506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Medical Group</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stern Cardiovascular Foundation</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Clinic</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart &amp; Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Hanover</city>
        <state>Göttingen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefässzentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus-Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASKLEPIOS Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKE - Universitäres Herzzentrum GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Univ. München - Grosshadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.impulse-dynamics.com/us/</url>
    <description>Impulse Dynamics Website</description>
  </link>
  <reference>
    <citation>Kadish A, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Abraham WT. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011 Feb;161(2):329-337.e1-2. doi: 10.1016/j.ahj.2010.10.025. Erratum in: Am Heart J. 2011 Jun;161(6):1220.</citation>
    <PMID>21315216</PMID>
  </reference>
  <reference>
    <citation>Abraham WT, Burkhoff D, Nademanee K, Carson P, Bourge R, Ellenbogen KA, Parides M, Kadish A; FIX-HF-5 Investigators and Coordinators. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Am Heart J. 2008 Oct;156(4):641-648.e1. doi: 10.1016/j.ahj.2008.05.019.</citation>
    <PMID>18926146</PMID>
  </reference>
  <reference>
    <citation>Neelagaru SB, Sanchez JE, Lau SK, Greenberg SM, Raval NY, Worley S, Kalman J, Merliss AD, Krueger S, Wood M, Wish M, Burkhoff D, Nademanee K. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm. 2006 Oct;3(10):1140-7. Epub 2006 Jul 8.</citation>
    <PMID>17018340</PMID>
  </reference>
  <reference>
    <citation>Abraham WT, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Kadish A; FIX-HF-5 Investigators and Coordinators. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail. 2011 Sep;17(9):710-7. doi: 10.1016/j.cardfail.2011.05.006. Epub 2011 Jun 22.</citation>
    <PMID>21872139</PMID>
  </reference>
  <reference>
    <citation>Abraham WT, Lindenfeld J, Reddy VY, Hasenfuss G, Kuck KH, Boscardin J, Gibbons R, Burkhoff D; FIX-HF-5C Investigators and Coordinators. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design. J Card Fail. 2015 Jan;21(1):16-23. doi: 10.1016/j.cardfail.2014.09.011. Epub 2014 Oct 5.</citation>
    <PMID>25285748</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Chronic heart disease</keyword>
  <keyword>Cardiac contractility modulation</keyword>
  <keyword>CCM</keyword>
  <keyword>CHF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

